ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

The Beacon (Audio)

The Beacon (Audio)

Por: H. Jack West, MD

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

75 episodios disponibles

Latest episodes of the podcast The Beacon (Audio)

Mostrando página 2 de 4

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055) 17/08/2018

Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054) 15/08/2018

Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053) 13/08/2018

Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052) 10/08/2018

Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051) 08/08/2018

Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050) 06/08/2018

Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049) 02/08/2018

Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048) 31/07/2018

Could Immunotherapy Replace Neoadjuvant Chemo for Muscle-Invasive Transitional Cell Carcinoma? Highlights from ASCO 2018 (BMIC-047) 28/07/2018

How do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046) 12/07/2018

Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045) 09/07/2018

Is the Survival Benefit from Dacomitinib on the ARCHER-1050 Trial Enough to Make it a Contender as First Line Treatment for EGFR Mutation-Positive NSCLC Today? (BMIC-044) 05/07/2018

The Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043) 02/07/2018

Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042) 28/06/2018

IMpower131: What is the Role for the Carbo/Nab-Paclitaxel/Atezolizumab Combination for Advanced Squamous NSCLC? (BMIC-041) 25/06/2018

Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 Under 1%, & High TMB? New Data from CheckMate 227 (BMIC-040) 22/06/2018

KEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039) 20/06/2018

KEYNOTE-042: Should Pembrolizumab Replace Chemo for a Broader Population of Patients with Advanced NSCLC? (BMIC-038) 18/06/2018

My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (BMIC-037) 23/05/2018

My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036) 21/05/2018

« Primera ‹ Anterior 1 2 3 4 Siguiente › Última »